The liver in the human stomach is a steadfast fortress that does not rest. It manages more than 500 vital processes per minute. This factory creates essential materials and compounds for life. It is also a center for purifying toxins, medicines, and hormones, and a repository of energy and immunity that spins wellness into our bodies without noise.
However, this silent guard may face harsh battles throughout life’s journey, with challenges accumulating on its walls as a result of chronic infections, recurring scars, and fibrosis, which paves the way for the occurrence of liver cancer, which represents about 90% of all primary liver tumors, and makes it the third cause of cancer deaths around the world.
Until recently, talking about liver cancer carried a lot of apprehension, especially when it was discovered in the late stages.
But the scene today is going through a historical turning point filled with signs of light, as modern medicine is experiencing a true biological and technical revolution that has completely changed the rules of the game, even for advanced cases. The therapeutic philosophy has transformed from mere attempts at limited control, to smart and comprehensive offensive strategies that combine the immunotherapy revolution, combination therapies, precise radiological interventions, and innovative wave fragmentation techniques to open the vast doors of hope for patients and their families, supported by the resolute global call: Early detection of tumors. It is the line between survival and departure.
This constant accumulation of fat, associated with type 2 diabetes and obesity, mimics in its destructive effect (if neglected) that of viruses, transforming active cells into stiff, fibrous tissue that is beyond genetic control, causing cirrhosis of the liver, which is the fertile ground for the emergence of tumors.
The tumor does not grow suddenly, but rather is the result of a long course of chronic inflammation and is often silent at first and results from several factors, the most prominent and important of which are chronic hepatitis viruses such as hepatitis B and C (HBV-HCV).
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as a silent and terrifying enemy as a result of contemporary unhealthy transformations.
This continuous accumulation of fat, associated with type 2 diabetes and obesity, mimics in its destructive effect (if neglected) the effect of viruses, transforming active cells into stiff fibrous tissue that is out of genetic control, causing liver cirrhosis, which is the fertile ground for the emergence of tumors, in addition to environmental toxins such as aflatoxins resulting from poor storage of grains.
The biggest deception here lies in the complete absence of symptoms at first, as the tumor grows inside the lobes without pain, taking advantage of the absence of sensory nerve endings in the internal liver tissue, and the patient lives for months in deceptive peace while the disease progresses inside.
When signs of the disease begin to appear, they are often late and appear in the form of general weakness and unexplained loss of appetite and weight, accompanied by pain or a feeling of fullness in the right upper quadrant of the abdomen.
As the tumor progresses, obstruction of the bile ducts and bile may occur, and fluid may form in the peritoneal cavity, causing ascites. When this stage occurs, the old traditional treatments were powerless, offering only limited options that exhausted the rest of the patient’s body.
Which highlights the utmost importance of breaking this silence with regular screening to detect cancer at an early stage to facilitate its effective treatment.
The difference between complete recovery and palliative control is always associated with the moment of early detection, and therefore international medical recommendations tend to include all people at high risk, namely patients with cirrhosis of the liver for any reason and carriers of Hepatitis B virus, in a regular periodic examination program every six months, which includes ultrasound examination and analysis of tumors and alpha-fetoprotein in the blood.
Here the pivotal role of primary health care doctors, family medicine and general practitioners is highlighted. They are the first line of defense that protects the patient by regularly referring them to this examination, which ensures that the tumor is captured when it is at its first size, and opens the doors to radical solutions such as surgical intervention such as resection or liver transplantation, or local burning using thermal frequency, microwaves, or one of the modern methods.
Surgical resection remains the ultimate solution when there is a definite tumor, stable liver function, no portal hypertension, and no increased jaundice. When the efficiency of the liver deteriorates, liver transplantation emerges as a saving option that removes the tumor and replaces the cirrhotic liver with another healthy liver. If the surgical scalpel is not possible, local cauterization with thermal frequency or microwave intervenes to annihilate small masses. This local cauterization is no less effective than resection for tumors that are less than 3 centimetres.
Among the modern methods for early detection of liver cancer that are currently being evaluated in international guidelines and recommendations are the following three:
- Specific Biomarkers: Using more sensitive indicators such as alpha-fetoprotein class III (AFP-L3) and prothrombin protein induced by vitamin K deficiency (DVK/PIVKA-II), allowing detection of molecular signals in their infancy.
- Innovative liquid biopsies: This technology is a quantum leap; Drawing a simple blood sample allows us to track the circulating tumor DNA (ctDNA) and circulating cells (CTCs) in the bloodstream, which eliminates the need for traditional surgical liver biopsies, which have complications, even if they are minor.
- Genomic Profiling & Personalized Medicine: Medicine has transformed into the concept of tailored treatment tailored to the patient. By reading the genetic mutations of the tumor, a molecular map is drawn that precisely identifies its strengths and weaknesses, to direct therapeutic strikes that hit the target alone and leave healthy cells safe.
Modern treatment map
Medical accuracy today depends on classifying the patient’s condition according to three factors: the size and spread of the tumor, the integrity of the remaining liver functions, and the patient’s general health condition.
Accordingly, modern treatment options are distributed in an integrated system under the jurisdiction of international academies, the most important of which are the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the National Comprehensive Cancer Network in America (NCCN), which rely on the Barcelona classification system for liver cancer, determining the stage of the disease, and treatment recommendations according to the stage.
Here it must be noted that the preference between one treatment method and another is subject to the agreement of the Multidisciplinary Medical Team (MDT), which has led to much better results based on clinical trials.
Surgical resection remains the ultimate solution when there is a specific tumor, stable liver function, no elevation of portal vein pressure, and no increased jaundice.
When the efficiency of the liver deteriorates, liver transplantation emerges as a saving option that removes the tumor and replaces the cirrhotic liver with another healthy liver, provided that the condition adheres to specific standards, the most important of which is Milan International.
If the surgical scalpel is not possible, local cauterization using thermal frequency or microwave is used to destroy small masses. This local cauterization is no less effective than excision for tumors that are less than 3 centimetres.
In the intermediate stages, when the number of tumors is more than 3 and the size may be large, interventional radiology offers targeted arterial chemotherapy (TACE) to directly inject the tumors and stifle them, or injection with arterial radioactive particles (TARE).
Stereotactic Body Radiation Therapy (SBRT) has also made a qualitative breakthrough. It directs extremely intense external radiation doses to destroy the tumor’s DNA in its location next to the major vessels without harming healthy tissue.
One of the most pioneering developments in recent years is the combination of chemical arterial injection (TACE) with pharmaceutical drugs. This combination promises great success and effectiveness, and it is expected that these techniques will be recommended by international associations in the near future.
In addition to this, Histotripsy, which is the latest technology and is currently being widely used, destroys cells mechanically and effectively through microscopic bubbles without heat or radiation.
When the disease progresses beyond the borders of the liver or a clot occurs in the liver blood vessels, which is known as advanced liver cancer, treatment is given with modern systemic and immunological medications (Systemic & Immunotherapy), which have radically changed the treatment method.
Drug treatment with sorafenib began in 2008, and for about 10 full years it was the only drug approved in the arena for these patients. Then, systemic and immunological drugs were approved since then until now, and it created a qualitative breakthrough for these patients. The joint alliances have created a qualitative leap in the medical community.
At the forefront of immunotherapy was the combination of atezolizumab and bevacizumab as the first standard option, followed by the global STRIDE Protocol, which achieved a qualitative leap by combining Durvalumab with Tremelimumab.
In a medical update, the alliance of Nivolumab and Ipilimumab demonstrated distinctive effectiveness in destroying stubborn tumors. The therapeutic innovations did not stop there. Rather, an innovative alliance combining the drug Camrelizumab and Rivoceranib shone in the medical sky and proved successful.
In the event that there are solid contraindications that prevent the use of these advanced immunotherapies, such as the patient suffering from active autoimmune diseases or having previously undergone an organ transplant, Lenvatinib or Sorafenib remains the best and safe traditional option as a first-line multi-kinase inhibitor.
For second lines of treatment, when tumors appear stubborn and begin to progress again, smart drugs such as Regorafenib and Cabozantinib emerge, in addition to the drug Ramucirumab for patients with high levels of alpha-fetoprotein (AFP ≥ 400 ng/mL), so that this late arsenal closes the remaining genetic gaps and continues the process of clinical blockade of the tumor and deprivation of its cells. Of the ways of life.
One of the most pioneering developments in recent years is the integration of chemical arterial injection (TACE) with pharmaceutical drugs. This combination heralds great success and effectiveness, and it is expected that these techniques will be recommended by international associations in the near future.
It is very important to mention that careful follow-up after treatment methods is very important to prevent relapse and rapid intervention to prevent the condition from worsening.
An important example of the uses of artificial intelligence
Modern medicine no longer waits for the results of treatment to judge failure or success, but rather uses artificial intelligence (AI) to decipher the future, where radioomics techniques and deep learning algorithms are combined to predict the extent of liver tumors’ response to stereotactic radiotherapy (SBRT) before administering the first dose.
These intelligent models analyze thousands of digital features that are invisible to the human eye in CT and MRI images, such as the exact texture of the tumor and the distribution of blood vessels surrounding it. By linking this data to the patient’s genetic profile, artificial intelligence can identify tumors with high radiation resistance with an accuracy of more than 88%.
The first line of defense begins with health education about the dangers of fatty liver, combating obesity, comprehensive vaccination against Hepatitis B and testing for Hepatitis C to treat those infected immediately before the cirrhosis stage, quality infection control in all medical facilities, dissemination of safe blood transfusion programs, and avoiding wrong practices such as drug abuse.
This digital integration provides doctors with a golden opportunity to modify the treatment plan, raise the radiation dose, or move immediately to another treatment option, which saves the patient from wasting valuable time on treatments that may not bear fruit and embodies the true meaning of future biology and the era of comprehensive medical digitization.
In the age of social media, patients face many false claims and misinformation. Giving in to these lies is not just a financial loss, but rather a biological crime committed by the patient against his body, and a clear neglect of minutes and seconds that make the difference between survival and death.
Delaying the start of approved medical treatment based on solid scientific evidence (Evidence-Based Medicine) and precise laboratory evidence documented by international governing organizations gives the tumor a golden opportunity to break the blockade, penetrate the major blood vessels, and spread comprehensively cancerous throughout the body, transforming an early clinical condition that could have been completely cured and erased through the approved treatment, into an advanced, incurable condition in front of which all solutions fade and are difficult to treat. Therefore, health awareness of the danger of this must be increased, while demanding that the legislator increase its severity. Punishment for this crime.
Defeating this disease is a major societal epic that requires everyone’s cooperation and cooperation between governmental institutions and non-governmental institutions, including civil society institutions and the private sector, and calling on them to invest seriously and sustainably to support local scientific research and finance molecular biology research, while supporting the registration of patients in global clinical trials, and providing the latest interventional radiology devices, is a duty that contributes directly to the localization of smart treatments and reducing their exorbitant cost.
Solid scientific research is the only stronghold in which weapons of victory and continuous updates to healing protocols are made, and with the dissemination of societal preventive culture, medical awareness must transform into an established daily culture and sterling societal behavior.
The first line of defense begins with health education about the dangers of fatty liver, combating obesity, comprehensive vaccination against Hepatitis B and testing for Hepatitis C to treat those infected immediately before the stage of cirrhosis, quality infection control in all medical facilities, dissemination of safe blood transfusion programs, and avoiding wrong practices such as drug abuse.
We also work to sanitize the environment to prevent grain contamination with aflatoxin, while activating regular periodic screening for early detection of liver cancer, which raises complete cure rates to more than 70% with treatment in the early stages of cancer.
The victory over liver cancer in our Arab world has become an established scientific fact led by the sobriety of the modern medical arsenal, and protected by building bridges of cooperation and strategic partnership with major international liver societies.
Let this article be an invitation and a call to intensify efforts and keep pace with global therapeutic evidence in investing in scientific research and localizing innovative treatments.
Every regular examination that we adhere to today is a safety valve that guards the factory of life in our bodies, and restores the pulse and hope for the fight against liver cancer throughout the great Arab world.
The opinions expressed in the article do not necessarily reflect the editorial position of Al Jazeera Network.